In a report released today, Michael Matson from Needham maintained a Buy rating on Merit Medical Systems, with a price target of $108.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Matson has given his Buy rating due to a combination of factors including Merit Medical Systems’ strong financial performance in the second quarter of 2025. The company exceeded market expectations in both revenue and earnings per share, leading to an upward revision in their 2025 financial guidance. This positive adjustment is partly attributed to a significant reduction in the anticipated tariff impact, which has improved the company’s profitability outlook.
Furthermore, despite a downward revision in the sales forecast for WRAPSODY due to reimbursement delays, the company is taking proactive steps by planning to submit a TPT application. Additionally, Merit Medical Systems demonstrated solid organic revenue growth and improved both gross and operating margins year-over-year. The increase in free cash flow also highlights the company’s effective execution of its strategic initiatives, supporting the Buy rating recommendation.
Matson covers the Healthcare sector, focusing on stocks such as TransMedics Group, Merit Medical Systems, and Conmed. According to TipRanks, Matson has an average return of -7.0% and a 37.80% success rate on recommended stocks.
In another report released on July 16, Robert W. Baird also maintained a Buy rating on the stock with a $112.00 price target.